Agios Pharmaceuticals (AGIO) Assets Average (2013 - 2026)

Agios Pharmaceuticals' Assets Average history runs 14 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• Quarterly Assets Average fell 22.88% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 22.88% YoY) and the FY2025 annual result came in at $1.5 billion, up 13.85% from the prior year.
• Assets Average was $1.2 billion for Q1 2026 at Agios Pharmaceuticals, down from $1.3 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.7 billion in Q4 2024 and bottomed at $811.4 million in Q2 2024.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2026 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average sank 40.68% — and 2025, when it jumped 86.52%.
• Agios Pharmaceuticals' Assets Average stood at $1.2 billion in 2022, then slipped by 19.62% to $972.2 million in 2023, then surged by 77.69% to $1.7 billion in 2024, then dropped by 22.35% to $1.3 billion in 2025, then decreased by 7.48% to $1.2 billion in 2026.
• Business Quant data shows AGIO's Assets Average at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.